Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program

Fanny Le Du; Matthieu Carton; Thomas Bachelot; Mahasti Saghatchian; Barbara Pistilli; Étienne Brain; Delphine Loirat; Laurence Vanlemmens; Thomas Vermeulin; George Emile; Anthony Gonçalvès; Mony Ung; Marie Robert; Anne Jaffré; Isabelle Desmoulins; Christelle Jouannaud; Lionel Uwer; Jean Marc Ferrero; Marie‐Ange Mouret‐Reynier; William Jacot; Michaël Chevrot; Suzette Delaloge; Véronique Dièras

doi:10.1093/oncolo/oyad137

Abstract

Among patients with relapsed HER2+ MBC, the receipt of adjuvant trastuzumab did not independently predict for worse outcomes when adjusted to other prognostic factors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Du et al. (2023) studied this question.

synapsesocial.com/papers/69daaff44a1e15904c835b08 https://doi.org/10.1093/oncolo/oyad137

View Full Paper

Ask AI

Bookmark

Share

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program

Abstract

Discussion

Cite This Study

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program

Abstract

Discussion

Cite This Study

Keep reading

Keep reading